The worldwide incidence of malignant mesothelioma is increasing and in the UK is expected to peak at over 3000 cases *per annum* within 5 years ([@bib11]). However, it will continue to pose a global public health threat for decades thereafter, owing to the continued use of asbestos in developing economies. Much work has focused on developing new therapies, both pharmacological and surgical, yet clinical outcomes remain dire. Without a better understanding of the fundamental biology of this cancer, it is unlikely that significant breakthroughs will occur.

*In vitro* studies have shown that selective inhibition of the proteasome with the drug bortezomib will induce cell-cycle arrest in cultured malignant mesothelioma cell lines ([@bib7]). Although the mechanism remains unclear, when used to treat drug-resistant cases of malignant myeloma, bortezomib has been shown to induce endoplasmic reticulum (ER) stress, which can trigger both cell-cycle arrest and cell death ([@bib19]). Endoplasmic reticulum stress is now recognised to have a role in the pathophysiology of many human diseases including cancer ([@bib14]). This reflects both increased protein misfolding within hypoxic solid tumours and dysregulation of the secretory pathway in malignant cells ([@bib4]; [@bib19]). Moreover, an intact ER stress-signalling pathway is necessary for the growth of some tumours ([@bib4]). The adaptive response to ER stress, or 'unfolded protein response\', comprises mechanisms to regulate new protein translation and to induce genes that enable adaptation to stress ([@bib14]; [@bib13]). Mesothelial cells generate large quantities of surface glycoproteins to help lubricate the pleural space, and so dysregulation of their synthesis is likely to be associated with ER stress.

Endoplasmic reticulum stress activates multiple transmembrane sensors including protein kinase R-like kinase (PERK) ([@bib14]). PERK mediates inhibition of global protein translation through phosphorylation of eukaryotic translation initiation factor 2*α* (eIF2*α*), which reduces the load of newly synthesised proteins entering the ER lumen ([@bib21]; [@bib8]). Once phosphorylated, eIF2*α* is unable to support new protein synthesis ([@bib10]); although a subset of ER stress-responsive proteins including transcription factor C/EBP homologous protein (CHOP) is induced under these conditions ([@bib25]). Target genes of CHOP, which include growth arrest of DNA damage 34 (GADD34), appear to have a role in the toxicity seen during chronic ER stress, because cells lacking CHOP are protected from ER-stress-induced death ([@bib27]; [@bib15]).

We hypothesised that markers of ER stress in biopsy specimens from cases of malignant mesothelioma would reflect the endogenous level of ER stress signalling within the tumour and provide prognostic information. We chose to measure protein expression of CHOP, GADD34 and BiP in formalin-fixed paraffin-embedded (FFPE) samples, because CHOP and GADD34 have both been linked with the toxic consequences of ER stress, whereas BiP levels are known to correlate with cytoprotection. Herein, we report that GADD34 expression is correlated with the degree of mesothelial cell differentiation, whereas CHOP expression is an independent predictor of prognosis in malignant mesothelioma.

Materials and methods
=====================

Ethics and consent
------------------

Ethical approval for the use of samples and data collection was granted by the Research Ethics Committee (REC reference 09/H0311/21). All cases of malignant mesothelioma diagnosed at Papworth Hospital (Cambridge, UK) between 2005 and 2010 were identified from hospital records, and the FFPE biopsy tissue blocks were retrieved from the pathology department store along with their associated histology slides. Clinical data relating to the cases were extracted from hospital records.

Antibodies
----------

The antibodies used in this study were: rabbit polyclonal anti-GADD34 1 : 100 (10449-1-AP; Proteintech, Chicago, IL, USA); rabbit monoclonal anti-BiP 1 : 200 (C50B12; Cell Signaling Technology, Boston, MA, USA); and rabbit polyclonal anti-GADD153/CHOP 1 : 300 (ab59396; Abcam, Cambridge, UK). The following antibodies were tested using various conditions but were ineffective in detecting differences in antigen expression in response to ER stress: rabbit polyclonal anti-PPP1R15A/GADD34 (HPA202240, Prestige antibodies; Sigma, Dorset, UK); rabbit polyclonal anti-GADD34 (SC-824; Santa Cruz Technologies, Inc., Santa Cruz, CA, USA); and mouse monoclonal anti-GADD153/CHOP (ab11419; Abcam).

Cell clots
----------

Cultured cells were collected by trypsinisation and pelleted by centrifugation, washed with PBS and resuspended in Cytofix reagent (Surgipath, Milton Keynes, UK) for at least 2 h at room temperature. Cell clots were generated from these fixed cells by the addition of human plasma and bovine thrombin (Diagen Diagnostic Reagents Ltd, Oxfordshire, UK) with incubation at 37 °C until clot formation. The clot was fixed in 10% v/v formalin, dehydrated through serial ethanol washes and embedded in paraffin wax.

Tissue microarray
-----------------

One-hundred and thirty-five cases of malignant mesothelioma were included in the study. For each tissue block, a haematoxylin and eosin-stained section was re-examined by an experienced histopathologist, and at least three representative regions of tumour were identified. Cores of tissue measuring 0.6 mm in diameter were taken from each region of each block and were used to generate a tissue microarray (TMA) comprising three blocks. Normal pleura, liver and kidney controls were distributed at random intervals throughout the TMA. Sections of 3 *μ*m were prepared and stained as detailed below. Every 50th section was stained with haematoxylin and eosin for monitoring of morphology and quality of cores.

Immunohistochemistry
--------------------

Sections were baked in an oven at 65 °C for 1 h. PT link tanks (Dako, Glostrup, Denmark) were used to perform deparaffinisation and heat-induced epitope retrieval (EnVision FLEX Target Retrieval Solution High pH; Dako). All slides were incubated for 20 min at 97 °C and left in buffer (EnVision FLEX wash buffer; Dako) at room temperature for a minimum of 5 min to cool down. Staining was performed using an automated immunostainer (AutostainerLink48; Dako). The protocol was as follows: slides were incubated for 5 min in an endogenous block (EnVision FLEX peroxidase-blocking reagent; Dako) and then incubated with antibody for 30 min. MNF116, mesothelin, vimentin and calretinin had an additional step of incubating sections with mouse linker (EnVision FLEX/mouse(linker); Dako) for 15 min. Then all sections were incubated for 30 min in labelled polymer (EnVision FLEX/HRP; Dako). Each individual stage was followed by buffer rinses (EnVision FLEX wash buffer; Dako). Staining was visualised using the chromogen 3,3′-diaminobenzidine for 10 min, counterstained with haematoxylin (EnVision FLEX; Dako) for 5 min and manually cover-slipped (Surgipath) with DePeX mounting medium (VWR International, Poole, UK).

To quantify ER stress signalling in FFPE tissue samples, we tested the specificity of commercially available antibodies against the antigens BiP, CHOP and GADD34. To this end, human HCT116 cells and mouse embryonic fibroblasts were cultured under basal conditions or conditions known to induce ER stress. Thapsigargin inhibits the sarco/endoplasmic reticulum calcium ATPase that maintains ER luminal calcium levels, and so induces ER stress by causing depletion of ER calcium. Based on previous studies, under basal conditions, HCT116 cells were expected to show no or very low expression of CHOP and GADD34 with modest expression of BiP ([@bib16], [@bib17]; [@bib9]; [@bib15]). Antibodies for BiP, CHOP and GADD34 were examined for their ability to distinguish between unstressed cells and ER stressed cells ([Figure 1](#fig1){ref-type="fig"}). To mimic FFPE biopsy material, cell clots were fixed in formalin and embedded in paraffin. An antibody was assessed as detecting its antigen only if staining were higher in ER-stressed cells compared with controls. Antibodies tested that failed to pass these criteria are listed in Materials and Methods. For each antigen, the antibodies capable of reliably identifying ER-stressed FFPE samples were: rabbit polyclonal anti-GADD34 (10449-1-AP; Proteintech); rabbit monoclonal anti-BiP (C50B12; Cell Signaling Technology); and rabbit polyclonal anti-GADD153/CHOP (ab59396; Abcam).

Scoring and statistical analysis
--------------------------------

Survival was assessed from the date of histological diagnosis. Data analysis was performed with SPSS v17.0 (SPSS Inc., Woking, UK) and the R software environment. Univariate survival analysis used the log-rank test (LR), and multivariable analysis was performed by Cox regression using a forward stepwise model based on likelihood ratios. Results were displayed graphically as Kaplan--Meier curves or box-and-whisker plots. To assess the utility of CHOP score as a prognostic marker, C-statistics (area under the ROC curve) were estimated from logistic regression models fitted to 1-year survival outcomes. A C-statistic value of 0.5 represents chance, whereas \>0.65 is considered clinical relevant ([@bib18]). Estimated C-statistics, 95% CIs and *P*-values for testing whether addition of CHOP significantly increased the C-statistic were calculated using the pROC package in R ([@bib20]). The predictive value of models was assessed using C-statistic calculated from receiver operator curve analysis, with median survival as the bivariate state variable. Differences in staining scores between histological groups were assessed by ANOVA with Bonferroni *post-hoc* test. Correlations between staining scores and histological subtypes were assessed by Spearman\'s correlation coefficient. *P*-values\<0.05 were considered statistically significant.

Results
=======

Patients represented in the mesothelioma tissue microarray
----------------------------------------------------------

Tissue blocks were identified for 135 cases of malignant mesothelioma biopsied at Papworth Hospital between 2005 and 2010. Of these, 84 had tumour tissue on at least one level of the TMA. In all cases where cores lacked tumour cells, the original material had been from CT-guided needle biopsies. Clinical data were complete to August 2012. The demographics of this group are presented in [Table 1](#tbl1){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}. Consistent with the known epidemiology of malignant mesothelioma, most patients were male (80.7%), had a positive history of exposure to asbestos (69.6%) and had a median age of 70 years at the time of diagnosis ([Table 1](#tbl1){ref-type="table"}). The majority of cases had a positive smoking history (70.1%), but only a minority were current smokers at the time of biopsy (8.7%). Most cases had a good performance status of 0 or 1 at the time of diagnosis (77%). Tumour International Mesothelioma Interest Group stage determined by CT scan at presentation was advanced (stages II--IV) in the majority of patients (79.8%). Twelve patients (8.9%) were alive at the time of data analysis.

Detection of ER stress markers in malignant mesothelioma
--------------------------------------------------------

Scoring of the TMA for markers of ER stress was performed in parallel by two observers (LED and DMR) blinded to the clinical data. For each core and each antigen, intensity of tumour staining was evaluated on a scale from 0 to 3 after the method by [@bib3]: 0, negative; 1, detectable but weak; 2, moderate but submaximal; or 3, maximal ([Figure 3](#fig3){ref-type="fig"}). In addition, the extent of staining was recorded as the proportion of malignant cells staining. Staining scores for each antigen were calculated as the sum of each intensity multiplied by the percentage of positive cells of that intensity, giving a range from 0 (0 × 100%) to 300 (3 × 100%). The score used in all subsequent analysis was the average across the available cores. When TMA slides were probed for expression of BiP, CHOP and GADD34, each showed a significant relationship with histological subtype ([Figure 4](#fig4){ref-type="fig"}). There was a positive correlation between GADD34 immunoreactivity and mesothelial differentiation status (Spearman\'s correlation coefficient 0.513; *P*=0.000). GADD34 staining was significantly stronger in epithelial mesothelioma compared either with biphasic tumours (*P*\<0.001) or with sarcomatoid tumours (*P*\<0.005). BiP also showed correlation with mesothelial differentiation, but this was less pronounced (Spearman\'s correlation coefficient 0.425; *P*=0.000). In contrast, staining for CHOP displayed a weak inverse correlation with mesothelial differentiation (Spearman\'s correlation coefficient −0.333; *P*\<0.006).

Univariate analysis
-------------------

Baseline demographic characteristics with prognostic significance on univariate analysis were histological subtype (*P*\<0.001), current smoking (*P*=0.01), Eastern Cooperative Oncology Group (ECOG) performance status (*P*\<0.001), radiographic stage (CT stage) (*P*=0.008 for stages individually; *P*=0.004 for stage IV *vs* I--III) and referral for chemotherapy (*P*\<0.001) ([Table 2](#tbl2){ref-type="table"}). In isolation, age and gender did not have an impact on survival ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}); however, as noted previously ([@bib5]), the composite European Organisation for Research and Treatment of Cancer (EORTC) prognostic score, which combines age, gender, histology, probability of diagnosis and leucocyte count, correlated significantly with prognoses (*P*=0.002 as a continuous variable and *P*\<0.001 using the validated threshold of 1.27) ([@bib5]) ([Table 2](#tbl2){ref-type="table"}, [Figure 2B](#fig2){ref-type="fig"}).

For the purposes of univariate analysis, histological scores were grouped into quintiles. Only CHOP score quintiles were associated with prognosis (*P*=0.005). Those cases staining in the top quartile of intensities had a median survival significantly shorter than that of the rest of the cohort (145±17 *vs* 486±55 days, *P*=0.002; [Figure 5A--D](#fig5){ref-type="fig"}). When cases were stratified by stage, a statistically significant difference persisted for early stage (stage I and II) ([Figure 5E--H](#fig5){ref-type="fig"}).

Multivariate analysis
---------------------

In multivariate analysis by Cox regression, CHOP score was a significant predictor of survival independent of histology, smoking, ECOG performance status, chemotherapy and EORTC prognostic score ([Table 3](#tbl3){ref-type="table"}). CT stage and chemotherapy were redundant when models included CHOP score. When CHOP score, performance status, histology, smoking and EORTC prognostic score were considered simultaneously using a forward stepwise model, the most parsimonious model retained only CHOP score and performance status (HR~CHOP\ score~ 0.332, *P*=0.014; HR~performance\ status~ 2.501, *P*=0.000; *n*=46). However, the addition of CHOP score to logistic regression models of other prognostic factors improved the C-statistic significantly only in the case of radiological staging ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

In this study, we have examined the expression levels of markers of ER stress in malignant mesothelioma, and correlated this with survival times. Levels of GADD34 correlated with mesothelial differentiation, whereas levels of CHOP staining predicted prognosis-independent histological subtype. Previous work has suggested that GADD34 may function as a tumour suppressor through its growth arrest and pro-apoptotic properties ([@bib6]; [@bib26]; [@bib12]; [@bib24]), although in our study it was not an independent predictor of survival. This may reflect a lack of statistical power, because selection of cases with the least GADD34 staining using an empirical cutoff of 175 appeared to identify a group with poor prognosis (not shown). Unfortunately, because of the rarity of mesothelioma, our cohort could not be efficiently divided into discovery and validation sets, and therefore this finding remains speculative and requires future validation. The close correlation between GADD34 staining and histological subtype suggests that GADD34 is unlikely to be an independent variable. Nevertheless, this correlation may indicate an important mechanistic link between loss of mesothelial differentiation and tumour aggressiveness. It is tempting to speculate that correction of the deficit of GADD34 might have therapeutic benefit. Indeed, treatment with chemotherapy and radiotherapy has previously been shown to upregulate GADD34 expression in cancer cells and to promote increased oncolytic viral replication, presumably through antagonising the antiviral effects of PKR ([@bib1], [@bib2]). It is noteworthy that during an effort to identify genes involved in tumour progression, an N-terminal truncated sequence of GADD34 was identified by subtractive hybridisation from a rat embryonic cell line ([@bib24]). This transcript, which was named progression elevated gene-3, was found to enhance tumour aggressiveness and promote angiogenesis *in vivo* ([@bib23]). Similar truncating mutations of GADD34 are frequent occurrences during transformation of rat cell lines ([@bib22]). The mechanism for the tumour-promoting activity is unclear but might plausibly involve a dominant-negative interaction with endogenous GADD34. We did not specifically attempt to detect this product of the GADD34 gene, and the antibody we used to detect GADD34 in histological specimens had been raised against a fusion protein, containing residues 304--569 of the 654 amino-acid human GADD34, and so would not have recognised most of the N-terminal portion of the protein.

Although GADD34 is a transcriptional target of CHOP in the context of cellular stress ([@bib15]), the two proteins demonstrated a weak reciprocal relationship in relation to mesothelial differentiation. It is possible that expression of GADD34 in benign mesothelium *in vivo* and in epithelioid malignant mesothelioma might occur through the alternate signalling pathways. Alternatively, the failure to express GADD34 through as-yet unidentified malignant processes might exaggerate the CHOP signal caused by ER stress. Since the transcriptional programme of CHOP includes at least 200 additional targets ([@bib15]), it is possible that their overexpression in such circumstances might contribute to adaptation of the tumour to ER stress and thus promote tumour growth.

In summary, we have constructed a TMA of a series of cases of malignant mesothelioma, and used this to examine the expression levels of markers of ER stress in this cancer. Our results suggest that CHOP may represent a useful biomarker of tumour aggression. This may prove useful in patient stratification and the development of anticancer strategies aimed at modulating ER stress, for example, the use of proteasome inhibitors and newer agents such as inhibitors of HSP90. The correlation of GADD34 with mesothelial differentiation may prove useful in the sub-classification of borderline histological cases.
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![Endoplasmic reticulum stress and its detection in FFPE samples. Human HCT116 cell clots were generated using human plasma and thrombin from unstressed cells and cells treated with 400 nℳ thapsigargin (Tg) to induce ER stress. Clots were fixed in formalin and embedded in paraffin to mimic the preparation of biopsy material. These were used to identify antibodies capable of distinguishing unstressed from ER-stressed cells by immunohistochemistry for BiP, CHOP and GADD34. Scale bar indicates 50 *μ*m.](bjc201366f1){#fig1}

![**Mesothelioma patient characteristics and prognosis.** Kaplan--Meier curves corresponding to demographic data. (**A**) ECOG performance status (0, blue; 1, green; 2, purple; and 3, orange). (**B**) EORTC prognostic score=0.55 (if white cell count \>8.3 × 10^9^ cells per l)+0.6 (ECOG performance status is 1 or 2)+0.52 (if histology probable)+0.60 (if histology is sarcomatoid)+0.60 (if gender is male); low \<1.27, high ≥1.27 ([@bib5]). (**C**) Histological sub-type. (**D**) Histological sub-type with sarcomatoid and biphasic combined as 'not epithelioid\'. Statistical significance is indicated in figures **A**--**D**, top right. Univariate survival analysis used the log-rank test. Points censored from the statistics because the patient remained alive at the time of analysis are indicated as crosses.](bjc201366f2){#fig2}

![**Tissue microarray stained for markers of ER stress.** (**A**) Tissue microarray of 0.6 mm cores of representative epithelioid, sarcomatoid and biphasic malignant mesothelioma stained with H&E × 40 (insert box × 100). (**B**) Representative images of tissue microarray cores stained for BiP, CHOP and GADD34, indicating intensities scored from 0 to 3 after the method by [@bib3]: 0, negative; 1, detectable but weak; 2, moderate but submaximal; or 3,maximal; × 40 (insert × 100).](bjc201366f3){#fig3}

![Correlation of ER stress markers with histological subtype. Box-and-whiskers plot of staining scores for BiP, GADD34 and CHOP in epithelioid, bisphasic and sarcomatoid mesothelioma. Statistical differences were calculated by ANOVA with Bonferroni *post-hoc* test.](bjc201366f4){#fig4}

![CHOP score predicts prognosis. Kaplan--Meier curves and box-and-whiskers plots of mesothelioma patient groups defined by CHOP score. (**A**, **B**) Upper (green) and lower (blue) quintiles of CHOP score. Median survivals±s.e.: CHOP high 145±0.17 days; CHOP low 486±48 days. (**C**, **D**) Upper quintile (green) and remaining cases (blue). Median survival±s.e.: CHOP high 145±0.17 days; CHOP low 486±55 days. Censored cases are represented by crosses. (**E**--**H**) Survival of CHOP-defined groups stratified by stage. (**E**, **F**) Stages I and II combined: CHOP high 145±45 days; CHOP low 568±145 days. (**G**, **H**) Stages III and IV combined: CHOP low 284±100 days; CHOP low 536±127 days.](bjc201366f5){#fig5}

###### Patient characteristics

                            **Number of patients**    **Number of patients available**  **(%)**
  ------------------------- ------------------------ ---------------------------------- ---------
  Gender                                                            135                  
   Male                     109                                                         80.7
   Female                   26                                                          19.3
  Histogy                                                           135                  
   Epithelioid              100                                                         74.1
   Biphasic                 22                                                          16.3
   Sarcomatoid              13                                                          9.6
  Smoking status                                                    127                  
   Ex-smoker                79                                                          62.2
   Current                  11                                                          8.7
   Never                    37                                                          29.1
  Asbestos exposure                                                 135                  
   Yes                      94                                                          69.6
  ECOG performance status                                           100                  
   0                        34                                                          34.0
   1                        43                                                          43.0
   2                        16                                                          16.0
   3                        7                                                           7.0
  CT stage                                                           84                  
   I                        17                                                          20.2
   II                       15                                                          17.9
   III                      29                                                          34.5
   IV                       23                                                          27.4
  Chemotherapy                                                      103                  
   Yes                      39                                                          37.9
   No                       64                                                          62.1
  Alive                                                             135                  
   Yes                      12                                                          8.9
  WCC                                                               128                  
   \>8.3                    84                                                          65.6

Abbreviations: CT=computed tomography; EORTC=European Organisation for Research and Treatment of Cancer; WCC=white cell count.

###### Parameters influencing survival in univariate analysis

  **Parameter**                     **Cut-off**          ***P*****-value**
  ------------------------ ----------------------------- -------------------
  Histology                        All subtypes          0.000
                                  Non-epithelioid        0.000
  Smoking                           All groups           0.031
                                  Current smoker         0.010
  ECOG PS                           All groups           0.000
                                  0--1 *vs* 2--3         0.000
  CT stage                          All groups           0.008
                                  I--III *vs* IV         0.004
  Chemotherapy                         Given             0.001
  EORTC prognostic score            All groups           0.002
                                      \<1.27             0.000
  CHOP score                       All quintiles         0.005
                             Top *vs* bottom quintiles   0.006
                            Top quintile *vs* remainder  0.002

Abbreviations: CHOP=C/EBP homologous protein; CT=computed tomography; EORTC=European Organisation for Research and Treatment of Cancer; PS=performance status.

###### Prognostic models involving pairwise combinations including CHOP score

  **Paired comparison**           **HR (Exp(B))**   **95% CI low**   **95% CI high**   ***P*****-value**   ***n***
  ------------------------------- ----------------- ---------------- ----------------- ------------------- ---------
  CHOP score                      0.469             0.243            0.902             0.023               67
  Histology                       1.939             1.243            3.023             0.003                
  CHOP score                      0.457             0.240            0.870             0.017               65
  Smoking                         1.647             1.021            2.657             0.041                
  CHOP score                      0.383             0.162            0.908             0.000               48
  ECOG performance status         2.646             1.725            4.061             0.000                
  CHOP score                      0.430             0.228            0.812             0.009               67
  EORTC prognostic score          3.477             1.845            6.550             0.000                
  CHOP score                      0.424             0.225            0.799             0.008               67
  EORTC prognostic score \<1.27   2.289             1.239            4.229             0.008                

Abbreviations: CI=confidence interval; EORTC=European Organisation for Research and Treatment of Cancer; Exp(B)=exponentiation of the B coefficient; HR=hazard ratio.

###### C-statistic value for the prediction of reaching median survival

  **Model**                                  **C-statistic**   Δ**C (*****P*****-value)**   **CI 95% low**   **CI 95% high**
  ----------------------------------------- ----------------- ---------------------------- ---------------- -----------------
  CHOP top quintile                               0.649                                         0.555             0.743
  Histology (all types)                           0.706                                         0.606             0.801
  Histology (all types)+CHOP top quintile         0.750                0.050 (ns)               0.653             0.859
  ECOG PS                                         0.826                                         0.712             0.941
  ECOG+CHOP top quintile                          0.895                0.069 (ns)               0.805             0.985
  EORTC score \<1.27                              0.667                                         0.567             0.767
  EORTC score \<1.27+CHOP top quintile            0.718                0.052 (ns)               0.613             0.825
  CT stage (all)                                  0.748                                         0.581             0.915
  CT stage (all)+CHOP                             0.855                0.107 (ns)               0.725             0.985
  CT stage (I--III *vs* IV)                       0.608                                         0.483             0.797
  CT stage (I--III *vs* IV)+CHOP                  0.797              0.188 (0.011)              0.657             0.936

Abbreviations: CHOP=C/EBP homologous protein; CI=confidence interval; CT=computed tomography; EORTC, European Organisation for Research and Treatment of Cancer; ns=not statistically significant.

ΔC indicates difference in C-statistic from reference value due to addition of CHOP score to the model.
